Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review
Frontiers in Pharmacology · 05.11.2026 · 17
DOI: 10.3389/fphar.2026.1871437 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2026. Verfasst von Shaban Mohammed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives Pharmacogenetic (PGx) testing holds promise for improving drug efficacy and safety by tailoring therapy to patients’ genetic profiles. One of the most clinically relevant applications is CYP2C19 testing to guide clopidogrel therapy, particularly in cardiovascular patients. As accessible healthcare settings, community pharmacies may provide a practical model for delivering PGx services. This systematic review evaluates the feasibility of implementing CYP2C19 genetic testing for clopidogrel management in community pharmacy settings.
Methods
A systematic search of PubMed, ProQuest, Cochrane Central, Scopus, and EBSCO was conducted from inception to 23 December 2025, following PRISMA guidelines. Eligible studies assessed CYP2C19 testing in community pharmacies. Outcomes of interest included clinical, operational, economic, patient-reported, and provider-reported measures.
Results
Of 42 studies initially screened, three prospective studies met the inclusion criteria. All evaluated pharmacist-led CYP2C19 testing models in community pharmacies. Testing success rates were high (98%–100%). However, only the point-of-care testing enabled rapid turnaround times. Patient-reported perceptions were generally favorable, with most considering pharmacies appropriate for PGx testing. Pharmacists reported added clinical value but cited barriers such as reimbursement challenges, workflow integration, and knowledge gaps. Economic findings were mixed: point-of-care testing showed potential cost savings at higher rates of genotype-guided therapy modification, while reimbursement limitations hindered implementation in other settings.
Conclusion
Community pharmacy-based PGx testing for clopidogrel provides preliminary evidence supporting operational feasibility. To support sustainable implementation, efforts should focus on establishing funding mechanisms, enhancing provider education, and integrating PGx testing into routine workflows.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
- Department of Pharmaceutical Life Sciences, Universiti Malaya, Kuala Lumpur, Malaysia.
- Dr. Fatina Imran Medical Complex Doha, Doha, Qatar.
- Qatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.
- Trauma and Vascular Research and Development at Hamad medical corporation, Doha, Qatar.
- Clinical Medicine Department, Weill Cornell Medical College, Doha, Qatar.
Zitieren
APA
Mohammed, S., Mohammed, N., Ali, Z., Ghariba, Y., Al-Muftah, W., Abdel-Latif, R., El-Menyar, A., & Sim, M. S. (2026). Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1871437
Vancouver
Mohammed S, Mohammed N, Ali Z, Ghariba Y, Al-Muftah W, Abdel-Latif R, et al. Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1871437
BibTeX
@article{Mohammed2026,
author = {Mohammed, Shaban and Mohammed, Nermin and Ali, Zainab and Ghariba, Yaser and Al-Muftah, Wadha and Abdel-Latif, Rania and El-Menyar, Ayman and Sim, Maw Shin},
title = {Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1871437}
}
EUVIMED